JP2004529914A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529914A5
JP2004529914A5 JP2002578974A JP2002578974A JP2004529914A5 JP 2004529914 A5 JP2004529914 A5 JP 2004529914A5 JP 2002578974 A JP2002578974 A JP 2002578974A JP 2002578974 A JP2002578974 A JP 2002578974A JP 2004529914 A5 JP2004529914 A5 JP 2004529914A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
amino
alkoxy
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002578974A
Other languages
English (en)
Japanese (ja)
Other versions
JP4590158B2 (ja
JP2004529914A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/010542 external-priority patent/WO2002080935A1/en
Publication of JP2004529914A publication Critical patent/JP2004529914A/ja
Publication of JP2004529914A5 publication Critical patent/JP2004529914A5/ja
Application granted granted Critical
Publication of JP4590158B2 publication Critical patent/JP4590158B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002578974A 2001-04-04 2002-04-03 グルコース再吸収阻害剤およびレチノイド−x受容体モジュレーターを含んで成る併用療法 Expired - Fee Related JP4590158B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28147901P 2001-04-04 2001-04-04
PCT/US2002/010542 WO2002080935A1 (en) 2001-04-04 2002-04-03 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators

Publications (3)

Publication Number Publication Date
JP2004529914A JP2004529914A (ja) 2004-09-30
JP2004529914A5 true JP2004529914A5 (cg-RX-API-DMAC7.html) 2005-12-22
JP4590158B2 JP4590158B2 (ja) 2010-12-01

Family

ID=23077475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002578974A Expired - Fee Related JP4590158B2 (ja) 2001-04-04 2002-04-03 グルコース再吸収阻害剤およびレチノイド−x受容体モジュレーターを含んで成る併用療法

Country Status (11)

Country Link
US (3) US6838442B2 (cg-RX-API-DMAC7.html)
EP (1) EP1392326B1 (cg-RX-API-DMAC7.html)
JP (1) JP4590158B2 (cg-RX-API-DMAC7.html)
CN (1) CN100384430C (cg-RX-API-DMAC7.html)
AT (1) ATE442148T1 (cg-RX-API-DMAC7.html)
CA (1) CA2443325C (cg-RX-API-DMAC7.html)
DE (1) DE60233655D1 (cg-RX-API-DMAC7.html)
ES (1) ES2331561T3 (cg-RX-API-DMAC7.html)
MY (1) MY148432A (cg-RX-API-DMAC7.html)
TW (1) TWI345978B (cg-RX-API-DMAC7.html)
WO (1) WO2002080935A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1384825A (zh) 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
BR0207846A (pt) 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Rxr活性化分子
US20030045553A1 (en) * 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
EP1270012A1 (en) * 2001-06-21 2003-01-02 Pfizer Products Inc. Use of pulmonary administration of insulin for treatment of diabetes
JP2005513026A (ja) * 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
KR20060105431A (ko) * 2003-06-27 2006-10-11 닥터 레디스 리서치 파운데이션 발라글리타존 및 당뇨병치료제 화합물을 포함하는 조성물
CN1319956C (zh) * 2003-09-12 2007-06-06 深圳市海粤门生物科技开发有限公司 一种噻唑烷二酮的衍生物及其药用制剂的制备方法和应用
CN1964706A (zh) 2004-03-17 2007-05-16 拉斯·M·拉森 通过抑制视觉周期预防视网膜病
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
CA2711673A1 (en) * 2008-01-31 2009-08-06 Astellas Pharma Inc. Pharmaceutical compositions for treating fatty liver disease
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
EP2291189B1 (en) 2008-05-22 2014-10-01 AstraZeneca AB Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
ES2380408T3 (es) 2008-08-28 2012-05-11 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2010141690A2 (en) * 2009-06-04 2010-12-09 Dara Biosciences, Inc. Indane analogs and use as pharmaceutical agents and process of making
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US9585857B2 (en) 2013-01-18 2017-03-07 Cornell University Methods of treating diseases associated with high-fat diet and vitamin A deficiency using retinoic acid receptor agonists
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
JOP20210009A1 (ar) 2018-07-19 2021-01-12 Astrazeneca Ab طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
JP2023536009A (ja) 2020-07-27 2023-08-23 アストラゼネカ・アクチエボラーグ ダパグリフロジンによる慢性腎疾患の処置方法
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
WO2024259383A2 (en) * 2023-06-14 2024-12-19 President And Fellows Of Harvard College Ion channel binders and uses thereof
IL329013A (en) 2023-12-15 2026-08-01 Astrazeneca Ireland Ltd SGLT2 inhibitors and baxadrostat for the treatment of chronic kidney disease and hypertension

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US651003A (en) * 1899-10-12 1900-06-05 Solomon W Bates Bicycle-pump.
JPH0253573A (ja) * 1988-08-11 1990-02-22 Nippon Riki Kk ラチェットレンチの製造法
US5731299A (en) * 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
JP2906978B2 (ja) * 1993-02-25 1999-06-21 田辺製薬株式会社 血糖降下剤
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2847695B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 血糖降下剤
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
PT859608E (pt) * 1995-09-18 2004-06-30 Ligand Pharm Inc Tratamento de niddm com agonistas de rxr
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
US5732199A (en) * 1996-09-25 1998-03-24 Behavior Tech Computer Corporation Control method and device of scanner with built-in plug-and-play printer port
ATE216704T1 (de) * 1996-12-26 2002-05-15 Tanabe Seiyaku Co Propiophenonderivate und verfahren zu ihrer herstellung
JP3055135B2 (ja) * 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
WO1998057635A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CN1384825A (zh) 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
EP1213296B1 (en) 1999-08-31 2004-04-14 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
PE20010580A1 (es) 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
JP2001192375A (ja) * 1999-10-29 2001-07-17 Takeda Chem Ind Ltd オキシイミノアルカン酸誘導体の結晶
AR031078A1 (es) 1999-10-29 2003-09-10 Takeda Pharmaceutical Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
CA2390923A1 (en) * 1999-11-10 2001-05-31 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
DE60121988T2 (de) * 2000-10-30 2007-02-15 Ortho-Mcneil Pharmaceutical, Inc. Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
SK287786B6 (sk) 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
US20030045553A1 (en) * 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators

Similar Documents

Publication Publication Date Title
JP2004529915A5 (cg-RX-API-DMAC7.html)
CA2443325A1 (en) Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
EP1522314B1 (en) Remedies for diseases caused by vascular contraction or dilation
KR100537843B1 (ko) 아릴피페리디놀및아릴피페리딘유도체및이들을함유하는약제
EP1698375B1 (en) Azetidine ring compounds and drugs comprising the same
AU754705B2 (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
JP2005519083A5 (cg-RX-API-DMAC7.html)
CA2442917A1 (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
CN1690047A (zh) 9-取代的二甲胺四环素化合物
IL123583A (en) 3-substituted -8-azabicyclo [3,2,1] oct-2-ene derivatives, their preparation and pharmaceutical compositions containing them
NZ270083A (en) N-aryl oxazolidin-2-one derivatives and medicaments
NZ305181A (en) Nodulisporic acid derivatives
JP2013531070A (ja) 置換3−フェニル−1,2,4−オキサジアゾール化合物
CN1039491C (zh) 四氢咔唑化合物及其制备方法和应用
CA2533747A1 (en) Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
RU2006133373A (ru) Производные имидазолина, обладающие св1-антагонистической активностью
JP2017036309A (ja) フェニル誘導体
EP2448924A2 (fr) Dérivés de pyrazoles, leur préparation et leur application en thérapeutique
KR20050085563A (ko) 하부요로증상을 치료하기 위한 알파-2-델타 리간드
EP2408756A1 (en) Alpha-(n-benzenesulfonamido)cycloalkyl derivatives
WO2006061136A3 (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer’s disease
US20020077342A1 (en) Heterocyclic derivatives useful as pharmaceutical agents
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
KR20140117301A (ko) 페닐 유도체를 함유하는 의약
WO2014157158A1 (ja) フェニル誘導体